• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HIV-1特异性逆转录酶抑制剂对逆转录酶中含有不同氨基酸取代的HIV-1突变株表现出不同的活性。

HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.

作者信息

Balzarini J, Karlsson A, Pérez-Pérez M J, Vrang L, Walbers J, Zhang H, Oberg B, Vandamme A M, Camarasa M J, De Clercq E

机构信息

Rega Institute for Medical Research, K. U. Leuven, Belgium.

出版信息

Virology. 1993 Jan;192(1):246-53. doi: 10.1006/viro.1993.1027.

DOI:10.1006/viro.1993.1027
PMID:7685964
Abstract

Serial passage of HIV-1 in CEM or MT-4 cell cultures in the presence of different HIV-1-specific reverse transcriptase (RT) inhibitors yielded mutant viruses which were resistant (i.e., 200- to 1000-fold less sensitive) to the homologous compounds. The RT of these mutant HIV-1 strains showed different amino acid substitutions depending on the class of the HIV-1-specific RT inhibitors. The following amino acid substitutions were found: 138 Glu-->Lys (TSAO-T), 181 Tyr-->Cys (nevirapine), 181 Tyr-->Cys (pyridinone), and 100 Leu-->Ile (TIBO R82150). Four TIBO (R82913)-resistant HIV-1 strains contained different amino acid substitutions: 103 Lys-->Asn (strain 2), 100 Leu-->Ile and 138 Glu-->Lys (strain B02), 100 Leu-->Ile and 181 Tyr-->Cys (strain 1), 100 Leu-->Ile and 188 Tyr-->His (strain B22). The level of cross-resistance (or sensitivity) highly depends on the nature of the amino acid substitutions. As a rule, the TSAO-resistant HIV-1 strains (138 Glu-->Lys) and TIBO (R82150 or R82913)-resistant HIV-1 strains (Leu 100-->Ile or 103 Lys-->Asn) are sensitive to the other HIV-1-specific RT inhibitors, whereas the amino acid change 181 Tyr-->Cys results in a significant reduction of sensitivity to all classes of the HIV-1-specific RT inhibitors.

摘要

在不同的HIV-1特异性逆转录酶(RT)抑制剂存在的情况下,HIV-1在CEM或MT-4细胞培养物中连续传代产生了对同源化合物具有抗性(即敏感性降低200至1000倍)的突变病毒。这些突变HIV-1毒株的RT根据HIV-1特异性RT抑制剂的类别显示出不同的氨基酸替换。发现了以下氨基酸替换:138位谷氨酸(Glu)替换为赖氨酸(Lys)(TSAO-T)、181位酪氨酸(Tyr)替换为半胱氨酸(Cys)(奈韦拉平)、181位酪氨酸(Tyr)替换为半胱氨酸(Cys)(吡啶酮)以及100位亮氨酸(Leu)替换为异亮氨酸(Ile)(TIBO R82150)。四株对TIBO(R82913)耐药的HIV-1毒株含有不同的氨基酸替换:103位赖氨酸(Lys)替换为天冬酰胺(Asn)(毒株2)、100位亮氨酸(Leu)替换为异亮氨酸(Ile)且138位谷氨酸(Glu)替换为赖氨酸(Lys)(毒株B02)、100位亮氨酸(Leu)替换为异亮氨酸(Ile)且181位酪氨酸(Tyr)替换为半胱氨酸(Cys)(毒株1)、100位亮氨酸(Leu)替换为异亮氨酸(Ile)且188位酪氨酸(Tyr)替换为组氨酸(His)(毒株B22)。交叉耐药(或敏感性)水平高度取决于氨基酸替换的性质。通常,对TSAO耐药的HIV-1毒株(138位谷氨酸(Glu)替换为赖氨酸(Lys))和对TIBO(R82150或R82913)耐药的HIV-1毒株(100位亮氨酸(Leu)替换为异亮氨酸(Ile)或103位赖氨酸(Lys)替换为天冬酰胺(Asn))对其他HIV-1特异性RT抑制剂敏感,而181位酪氨酸(Tyr)替换为半胱氨酸(Cys)的氨基酸变化导致对所有类别的HIV-1特异性RT抑制剂的敏感性显著降低。

相似文献

1
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.HIV-1特异性逆转录酶抑制剂对逆转录酶中含有不同氨基酸取代的HIV-1突变株表现出不同的活性。
Virology. 1993 Jan;192(1):246-53. doi: 10.1006/viro.1993.1027.
2
A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).人类免疫缺陷病毒1型逆转录酶中的单个保守氨基酸取代赋予了对(+)-(5S)-4,5,6,7-四氢-5-甲基-6-(3-甲基-2-丁烯基)咪唑并[4,5,1-jk][1,4]苯并二氮杂卓-2(1H)-硫酮(TIBO R82150)的抗性。
Mol Pharmacol. 1993 Jan;43(1):11-6.
3
Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.对人类免疫缺陷病毒1型逆转录酶第138位氨基酸进行定点诱变。
Virology. 2001 Feb 1;280(1):97-106. doi: 10.1006/viro.2000.0742.
4
Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.对1型人类免疫缺陷病毒特异性逆转录酶抑制剂耐药的不同1型人类免疫缺陷病毒逆转录酶的动力学
Mol Pharmacol. 1993 Apr;43(4):521-6.
5
Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.1-[(2-羟乙氧基)甲基]-6-(苯硫基)胸腺嘧啶衍生物的1型人类免疫缺陷病毒耐药模式
Mol Pharmacol. 1993 Oct;44(4):694-701.
6
Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy.用1型人类免疫缺陷病毒(HIV-1)特异性抑制剂组合治疗HIV-1感染的细胞,会产生与单药治疗不同的耐药模式。
J Virol. 1993 Sep;67(9):5353-9. doi: 10.1128/JVI.67.9.5353-5359.1993.
7
Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.1型人类免疫缺陷病毒特异性的[2',5'-双-O-(叔丁基二甲基甲硅烷基)-β-D-呋喃核糖基]-3'-螺-5"-(4"-氨基-1",2"-氧硫杂环戊二烯-2",2"-二氧化物)-嘌呤类似物显示出与1型人类免疫缺陷病毒特异性非核苷类似物不同的耐药谱。
Mol Pharmacol. 1993 Jan;43(1):109-14.
8
Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.非核苷类逆转录酶抑制剂与(-)2',3'-二脱氧-3'-硫代胞苷联合使用时对1型人类免疫缺陷病毒具有显著的抑制活性。
Mol Pharmacol. 1996 May;49(5):882-90.
9
Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720.1型人类免疫缺陷病毒逆转录酶对喹喔啉S-2720的耐药模式
J Virol. 1994 Dec;68(12):7986-92. doi: 10.1128/JVI.68.12.7986-7992.1994.
10
Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.1型人类免疫缺陷病毒膦甲酸钠耐药株的特征分析
Virology. 1995 Sep 10;212(1):58-68. doi: 10.1006/viro.1995.1453.

引用本文的文献

1
Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs.从 CH(CN)-DABO 到 CH(CN)-DAPY:HIV-1 非核苷类逆转录酶抑制剂发现中的支架跃迁。
Molecules. 2020 Mar 30;25(7):1581. doi: 10.3390/molecules25071581.
2
Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.叔丁基二甲基硅基螺环氨基氧硫代二氧噻嗪-胸腺嘧啶(TSAO-T)与 HIV-1 逆转录酶(RT)复合物的晶体结构重新定义了非核苷抑制剂结合口袋的弹性极限。
J Med Chem. 2011 Apr 28;54(8):2727-37. doi: 10.1021/jm101536x. Epub 2011 Mar 29.
3
Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives.
一类新型吡啶氧化物衍生物对人类免疫缺陷病毒的抑制作用。
Antimicrob Agents Chemother. 2003 Sep;47(9):2951-7. doi: 10.1128/AAC.47.9.2951-2957.2003.
4
Conformational analysis of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, based on quantum mechanical calculations.基于量子力学计算的非核苷类HIV-1逆转录酶抑制剂奈韦拉平的构象分析。
J Comput Aided Mol Des. 2001 Nov;15(11):997-1004. doi: 10.1023/a:1014881723431.
5
Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV.利用人类免疫缺陷病毒1型(HIV-1)逆转录酶的低保真性以及HIV-1基因组中的核苷酸组成偏向性来改变HIV的耐药性发展。
J Virol. 2001 Jul;75(13):5772-7. doi: 10.1128/JVI.75.13.5772-5777.2001.
6
Hybrid Ty1/HIV-1 elements used to detect inhibitors and monitor the activity of HIV-1 reverse transcriptase.用于检测抑制剂并监测HIV-1逆转录酶活性的杂交Ty1/HIV-1元件。
Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13905-10. doi: 10.1073/pnas.95.23.13905.
7
1,1,3-Trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: a new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity.1,1,3-三氧代-2H,4H-噻吩并[3,4-e][1,2,4]噻二嗪(TTD)衍生物:一类新型具有抗HIV-1活性的非核苷类人类免疫缺陷病毒1型(HIV-1)逆转录酶抑制剂。
Antimicrob Agents Chemother. 1998 Mar;42(3):618-23. doi: 10.1128/AAC.42.3.618.
8
Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.HIV-1逆转录酶与双(杂芳基)哌嗪(BHAP)U-90152之间复合物结构的独特特征解释了这种非核苷抑制剂的耐药突变。
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3984-9. doi: 10.1073/pnas.94.8.3984.
9
SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus.SRR-SB3,一种含二硫键的大环内酯类化合物,可抑制人类免疫缺陷病毒复制周期的晚期阶段。
Antimicrob Agents Chemother. 1997 Feb;41(2):262-8. doi: 10.1128/AAC.41.2.262.
10
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.人类免疫缺陷病毒逆转录过程中核苷类似物抗病毒活性及耐药性的机制
Antimicrob Agents Chemother. 1996 Mar;40(3):527-40. doi: 10.1128/AAC.40.3.527.